RESEARCH STATS
POOL
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
Interactions with Platform & by Email
PARTICIPANTS
Unique # Participated
VALIDATIONS
Responses Validated*
Number of executives repeatedly engaged by snail & email outreach
Interactions with Platform & by Email
Unique # Participated
Responses Validated*
*Engagement stats are ongoing and dynamic
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.
What`s New?
» Special discussions on the global economic climate and market sentiment
» Coverage on global competitiveness and key competitor percentage market shares
» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass™ research platform
» Complimentary updates for one year
» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Economic Outlook
The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.
The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.
Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Lung Cancer Diagnostics Market to Reach $4.7 Billion by 2030
The global market for Lung Cancer Diagnostics estimated at US$2.6 Billion in the year 2022, is projected to reach a revised size of US$4.7 Billion by 2030, growing at aCAGR of 7.8% over the period 2022-2030. Imaging Tests, one of the segments analyzed in the report, is projected to record 7.4% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Sputum Cytology segment is estimated at 7.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $675 Million, While China is Forecast to Grow at 11.3% CAGR
The Lung Cancer Diagnostics market in the U.S. is estimated at US$675 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.
Myriad Genetics, Inc.; F. Hoffmann-La Roche AG; Biocartis NV; Epigenomics AG; Biodesix, Inc.; Exosome Diagnostics, Inc.; Admera Health; Dr Lal PathLabs Ltd.; Guardant Health, Inc.; Oncimmune Holding PLC; Blueprint Genetics OY; CellMax Life, Inc.; Circulogene; BGI Genomics Co Ltd.; Inivata Ltd.
» Test (Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy, and Other Tests) » Type (Non-Small-Cell Lung Cancer (NSCLC), and Small-Cell Lung Cancer (SCLC) » and End-Use (Hospital Laboratories, Cancer Research Institutes, and Other End-Uses)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Early Detection of Lung Cancer Takes Precedence, Driving the Demand for Lung Cancer Diagnostics |
Non-small Cell Lung Cancer - The More Prominent of the Two Lung Cancer Types |
Imaging Tests Segment Dominates the Market, Molecular Tests Category to Witness High Growth |
US Leads the Lung Cancer Diagnostics Market, Asia-Pacific to Witness Fastest Growth |
Lung Cancer Diagnostics – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 48 Players Worldwide in 2022 (E) |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
Agilent Technologies Inc. (USA) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Illumina, Inc. (USA) |
NeoGenomics Laboratories, Inc. (USA) |
QIAGEN N.V. (The Netherlands) |
Thermo Fisher Scientific, Inc. (USA) |
Veracyte (USA) |
3. MARKET TRENDS & DRIVERS |
Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Early Diagnoses |
Age-Standardized Lung Cancer Rates for Select Countries |
Age-Standardized Lung Cancer Rates in Men for Select Countries |
Age Standardized Lung Cancer Rates in Women for Select Countries |
Lung Cancer-Specific Biomarkers to Spur Market Growth |
Select Lung Cancer Biomarkers |
New Potential Biomarker for Early Stage Lung Cancer Identified in a Recent NCI Study (2019) |
Advancements and Research Initiatives in Lung Cancer Diagnostics Space |
EFIRM Test for Detection of Lung Cancer-related EGFR Mutations in NSCLC Patients |
A Glance at Select Recent Launches of Lung Cancer Diagnostic Tests |
New Product Launches/Approvals in the Lung Cancer Diagnostics |
Recent Approvals |
Liquid Biopsies Grow in Value as a Diagnostic Tool Supporting Therapy Decisions in NSCLCs |
Effervescent Rate of New Innovations & Product Development Will Make Liquid Biopsy a Readily Available Option for Patients in the Coming Years |
High Cigarette Consumption/Rise in Prevalence of Smoking Increases the Incidence of Lung Cancer |
Cigarette Consumption Per Year Per Person Across Select Countries: 2016 |
Top 15 Countries with the Highest Smoking Rates: 2015 |
Increasing Number of Awareness Programs for Lung Cancer and Symptoms |
Growing Availability of Government/Private Funding for R&D to Develop Lung Cancer Diagnostics |
Table: National Cancer Institute Research Funding for Lung Cancer in US$ Million for the Years 2014 through 2017 |
Aging Demographics & Unhealthy Lifestyles Raise the Risk of Cancer |
Cancer Prone Sites based on Age |
Table: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Lung Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Imaging Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Sputum Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Sputum Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Sputum Cytology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Molecular Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Molecular Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Molecular Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Small-Cell Lung Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Small-Cell Lung Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Small-Cell Lung Cancer (SCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Hospital Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Cancer Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Lung Cancer Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
Lung Cancer Stats |
US Lung and Bronchus Cancer New Cases by Gender: 2019E |
US Lung and Bronchus Cancer Deaths by Gender: 2019E |
Incidence Rates* for Lung and Bronchus Cancer by Gender, 2011-2015 |
Death Rates* for Lung and Bronchus Cancer by Gender in the US, 2012-2016 |
Incidence Rates for Lung and Bronchus Cancer by Race/Ethnicity, 2011-2015 |
Reimbursement and Insurance Coverage for Lung Cancer Screening in the US |
CY 2019 Medicare Physician Fee Payment Levels for Low Dose CT Scan (LDCT) Screening |
CY 2019 Hospital Outpatient Prospective Payment System (HOPPS) Payment Levels for Low Dose CT Scan (LDCT) Screening |
Oncimmune’s EarlyCDT Lung to be commercialized in the US by Biodesix (2019) |
Market Analytics |
USA Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
JAPAN |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
Japan Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
CHINA |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
China Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
China Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
China Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
China Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
China Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
China Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
EUROPE |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
Europe Historic Review for Lung Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
FRANCE |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
France Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
France Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
France Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
France Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
France Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
France Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
GERMANY |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
Germany Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
UNITED KINGDOM |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
TABLE: UK Age-standardised Rate (per 100,00) of Lung Cancer Cases by Gender: 1980-2035P |
UK Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Spain Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Spain 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Spain Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Spain Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Spain 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Spain Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Spain Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Spain 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Russia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Russia 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Russia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Russia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Russia 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Russia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Russia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Russia 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
ASIA-PACIFIC |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Lung Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
AUSTRALIA |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E) |
Australia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Australia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Australia 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Australia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Australia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Australia 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Australia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Australia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Australia 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
INDIA |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E) |
Rise in Incidence of Lung Cancer in India |
Table: New Cancer Cases in India by Site: 2018 |
India Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
India Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
India 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
India Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
India Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
India 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
India Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
India Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
India 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
South Korea Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
South Korea 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
South Korea Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
South Korea Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
South Korea 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
South Korea Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
South Korea Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
South Korea 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
LATIN AMERICA |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E) |
Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
Latin America Historic Review for Lung Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Latin America 16-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030 |
Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Latin America Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Latin America 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Latin America Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Latin America 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Latin America Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Latin America 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Argentina Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Argentina 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Argentina Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Argentina Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Argentina 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Argentina Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Argentina Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Argentina 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Brazil Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Brazil 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Brazil Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Brazil Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Brazil 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Brazil Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Brazil Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Brazil 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Mexico Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Mexico 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Mexico Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Mexico Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Mexico 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Mexico Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Mexico Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Mexico 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Latin America Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Latin America 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Latin America Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Latin America 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Latin America Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Latin America 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
MIDDLE EAST |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E) |
Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
Middle East Historic Review for Lung Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Middle East 16-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030 |
Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Middle East Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Middle East 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Middle East Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Middle East 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Middle East Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Middle East 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
IRAN |
Iran Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Iran Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Iran 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Iran Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Iran Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Iran 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Iran Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Iran Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Iran 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Israel Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Israel 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Israel Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Israel Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Israel 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Israel Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Israel Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Israel 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Saudi Arabia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Saudi Arabia 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Saudi Arabia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Saudi Arabia 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Saudi Arabia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Saudi Arabia 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UAE Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
UAE 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
UAE Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UAE Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
UAE 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
UAE Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UAE Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
UAE 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Middle East Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Middle East 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Middle East Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Middle East 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Middle East Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Middle East 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
AFRICA |
Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E) |
Africa Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Africa Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Africa 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2023 & 2030 |
Africa Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Africa Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Africa 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2023 & 2030 |
Africa Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Africa Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Africa 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030 |
IV. COMPETITION |
(including Divisions/Subsidiaries - 48) |
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com
Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .
What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).
Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.
Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.
Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.
Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.
Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.
Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.
Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.